Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brivekimig

Next Previous
Drug Profile

Brivekimig

Alternative Names: Anti-TNFa and OX40L - Sanofi; Anti-TNFa/OX40L - Sanofi; NANOBODY®; SAR-442970; VHH antibody

Latest Information Update: 23 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanofi
  • Class Anti-inflammatories; Antihyperglycaemics; Monoclonal antibodies; Single-domain antibodies; Skin disorder therapies
  • Mechanism of Action OX40 ligand inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Crohn's disease; Focal segmental glomerulosclerosis; Hidradenitis suppurativa; Type 1 diabetes mellitus; Ulcerative colitis
  • No development reported Inflammation

Most Recent Events

  • 06 Nov 2025 Phase-II clinical trials in Hidradenitis suppurativa (Treatment-experienced) in United Kingdom, Japan, Canada, Australia, USA (SC) (NCT07170917)
  • 18 Sep 2025 Efficacy and adverse events data from a phase IIa trial in Hidradenitis suppurativa released by Sanofi
  • 12 Sep 2025 Sanofi plans a phase II trial for Hidradenitis Suppurativa (Treatment-experienced) in October 2025 (NCT07170917)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top